Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | HTT | P42858 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12295223 | 0.89 | KDM4E (0.74) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL12295458 | 0.88 | KDM4E (1.00) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL12295463 | 0.87 | KDM4E (0.78) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL12294732 | 0.85 | KDM4E (0.76) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL12294919 | 0.85 | KDM4E (0.76) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL12294733 | 0.84 | KDM4E (0.82) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL12295464 | 0.84 | KDM4E (0.73) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL24655998 | 0.79 | MAPK1 (0.74) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL12294568 | 0.79 | KDM4E (0.66) | KDM4ELMNAHTTSMN1; SMN2PKM | |
| SCHEMBL21096489 | 0.77 | CYP1A2 (0.80) | KDM4ESMN1; SMN2PKMNPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | claimed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | claimed |
| EP-2547678-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2016-03-16 | — | — | EP | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| WO-2012143796-A2 | ANTI-INFLAMMATION COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2012-10-26 | — | — | WO | disclosed |
| WO-2011113606-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065884-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | KDM4E 4439/4885LMNA 4132/4885HTT 3860/4885 |
| US-20140155387-A1 | Anti-Inflammation Compounds | NR0B1, NR0B2, NR5A2 | KDM4E 2886/4885LMNA 3721/4885HTT 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.